长非编码 RNA (lncRNA) 的研究因其在调节基因表达中的作用及其作为诊断生物标志物的潜力而受到广泛关注。这项系统综述和荟萃分析旨在评估高表达 lncRNA 对肝病患者（包括肝炎、肝硬化和肝细胞癌 (HCC) 患者）的诊断价值。在包括 PubMed 在内的多个电子数据库中进行了全面的文献检索、Embase、Web of Science 和 Cochrane 图书馆，截至 2024 年 7 月。如果他们调查肝病患者中 lncRNA 的表达并评估其诊断性能，则纳入研究。诊断准确性研究质量评估-2 (QUADAS-2) 工具用于评估纳入研究的质量。使用双变量随机效应模型计算汇总敏感性、特异性、诊断比值比 (DOR) 和汇总受试者工作特征 (SROC) 曲线。荟萃分析中纳入了涉及 888 个样本的 9 项研究。总生存期 (OS) 的汇总风险比 (HR) 为 2.01 (95% CI: 1.71-2.36)，表明高 lncRNA 表达与不良肝病结局之间存在显着相关性。亚组分析显示，组织样本的合并比值比 (OR) 为 1.99（95% CI：1.53-2.60），血液样本的合并比值比（OR）为 8.62（95% CI：1.16-63.71），表明基于血液的 lncRNA 具有更强的诊断价值。漏斗图表明发表偏倚最小，敏感性分析证实了研究结果的稳健性。高表达的lncRNA显示出作为肝病诊断生物标志物的巨大潜力，可提供非侵入性、准确且及时的诊断信息。尽管结果令人鼓舞，但仍需要进一步研究来标准化检测方法、阐明 lncRNA 的生物学功能并验证其在不同患者群体中的临床效用。将 lncRNA 生物标志物与传统诊断方法相结合可以提高诊断准确性并改善肝脏疾病的患者管理和结果。版权所有 © 2024 Zhu、Chen、Zhu、Zhang 和 Jin。

The study of long non-coding RNAs (lncRNAs) has gained significant attention due to their roles in regulating gene expression and their potential as diagnostic biomarkers. This systematic review and meta-analysis aimed to evaluate the diagnostic value of high-expression lncRNAs in liver disease patients, including those with hepatitis, cirrhosis, and hepatocellular carcinoma (HCC).A comprehensive literature search was conducted across multiple electronic databases, including PubMed, Embase, Web of Science, and Cochrane Library, up to July 2024. Studies were included if they investigated the expression of lncRNAs in liver disease patients and evaluated their diagnostic performance. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool was used to assess the quality of included studies. Pooled sensitivity, specificity, diagnostic odds ratios (DOR), and summary receiver operating characteristic (SROC) curves were calculated using a bivariate random-effects model.Nine studies involving 888 samples were included in the meta-analysis. The pooled hazard ratio (HR) for overall survival (OS) was 2.01 (95% CI: 1.71-2.36), indicating a significant association between high lncRNA expression and poor liver disease outcomes. Subgroup analyses revealed a pooled odds ratio (OR) of 1.99 (95% CI: 1.53-2.60) for tissue samples and 8.62 (95% CI: 1.16-63.71) for blood samples, suggesting a stronger diagnostic value for blood-based lncRNAs. The funnel plots indicated minimal publication bias, and sensitivity analyses confirmed the robustness of the findings.High-expression lncRNAs show significant potential as diagnostic biomarkers for liver diseases, offering non-invasive, accurate, and timely diagnostic information. Despite the promising results, further research is needed to standardize detection methods, elucidate the biological functions of lncRNAs, and validate their clinical utility in diverse patient populations. Integrating lncRNA biomarkers with traditional diagnostic approaches could enhance diagnostic accuracy and improve patient management and outcomes in liver disease.Copyright © 2024 Zhu, Chen, Zhu, Zhang and Jin.